The DNA diagnostic laboratory at San Francisco General Hospital is requesting continued funding as a Core laboratory that will provide DNA- based genotypic diagnoses for the Northern California Comprehensive Sickle Cell Center and serve as a diagnostic resource for other institutions. We will provide genotypic diagnoses for subjects in studies at the center and for patients whose clinical diagnosis cannot be determined readily using standard clinical testing, and will continue to develop improved methods for DNA diagnosis. Specifically, we will determine betas-globin and alpha-globin genotypes and beta-RFLP haplotypes of subjects to be enrolled in clinical and basic science studies at the Northern California Comprehensive Sickle Cell Center, which will be correlated with the information obtained in those studies. We will also provide genotype diagnoses for patients having difficult-to- diagnose hemoglobinopathies, including those for whom original diagnosis were not obtained before they were begun on chronic transfusion therapy, candidates for prenatal diagnosis whose mutations must be defined at the DNA level before prenatal diagnosis can be undertaken, and patients whose genotype diagnoses are obscured by complex interactions of multiple hemoglobinopathic genes. We will also continue to develop and adapt methods that offer advantages for DNA based diagnosis in sickle cell disease and other hemoglobinopathies. Methods that we are currently developing in our laboratory include direct sequence analysis of PCR product, denaturing gradient gel electrophoresis, single strand confirmational polymorphism, and gap PCR. These methods will provide greater breadth of diagnostic capabilities in our laboratory and may offer potential for replacing certain of the diagnostic method we currently employ. The availability of the sophisticated diagnostic methods used in this laboratory will complement and supplement the diagnostic abilities of the Core Hemoglobinopathy Laboratory.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Comprehensive Center (P60)
Project #
5P60HL020985-19
Application #
5213306
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
19
Fiscal Year
1996
Total Cost
Indirect Cost
Goodman, Jessica; Hassell, Kathryn; Irwin, David et al. (2014) The splenic syndrome in individuals with sickle cell trait. High Alt Med Biol 15:468-71
James, Ellen Butensky; Vreman, Hendrik J; Wong, Ronald J et al. (2010) Elevated exhaled carbon monoxide concentration in hemoglobinopathies and its relation to red blood cell transfusion therapy. Pediatr Hematol Oncol 27:112-21
Jenkins, Zandra A; Hagar, Ward; Bowlus, Christopher L et al. (2007) Iron homeostasis during transfusional iron overload in beta-thalassemia and sickle cell disease: changes in iron regulatory protein, hepcidin, and ferritin expression. Pediatr Hematol Oncol 24:237-43
Styles, Lori A; Abboud, Miguel; Larkin, Sandra et al. (2007) Transfusion prevents acute chest syndrome predicted by elevated secretory phospholipase A2. Br J Haematol 136:343-4
Kuypers, Frans A; Larkin, Sandra K; Emeis, Jef J et al. (2007) Interaction of an annexin V homodimer (Diannexin) with phosphatidylserine on cell surfaces and consequent antithrombotic activity. Thromb Haemost 97:478-86
Neumayr, Lynne D; Aguilar, Christine; Earles, Ann N et al. (2006) Physical therapy alone compared with core decompression and physical therapy for femoral head osteonecrosis in sickle cell disease. Results of a multicenter study at a mean of three years after treatment. J Bone Joint Surg Am 88:2573-82
Wilson, Leslie S; Moskowitz, Judith Tedlie; Acree, Michael et al. (2005) The economic burden of home care for children with HIV and other chronic illnesses. Am J Public Health 95:1445-52
Vichinsky, Elliott; Butensky, Ellen; Fung, Ellen et al. (2005) Comparison of organ dysfunction in transfused patients with SCD or beta thalassemia. Am J Hematol 80:70-4
Pakbaz, Zahra; Fischer, Roland; Treadwell, Marsha et al. (2005) A simple model to assess and improve adherence to iron chelation therapy with deferoxamine in patients with thalassemia. Ann N Y Acad Sci 1054:486-91
Banerjee, Tinku; Kuypers, Frans A (2004) Reactive oxygen species and phosphatidylserine externalization in murine sickle red cells. Br J Haematol 124:391-402

Showing the most recent 10 out of 207 publications